QIAGEN N.V. announced plans to advance its QuantiFERON latent tuberculosis (TB) test with a new fully automated Sample to Insight workflow and a separate AI-enabled risk stratification tool for TB progression, building on growing adoption of Diasorin LIAISON detection systems and a new automation partnership with Inpeco. The fully automated workflow is intended to position QuantiFERON as a complete Sample to Insight ecosystem, combining full automation, seamless traceability, and data-driven insights built on the foundation of QIAGEN?s more than 20 years of leadership in TB testing. Planned for launch in late 2027, this new workflow is designed for customers using Diasorin LIAISON systems aiming to automate the complete latent TB testing process without routine manual operator intervention, from preanalytical tube handling and incubation with Inpeco to detection on LIAISON systems. Through its partnership with Inpeco, QIAGEN is advancing total laboratory automation for QuantiFERON IGRA testing.
The collaboration brings two purpose-built innovations, a dedicated QuantiFERON aliquoting system and an intelligent incubation system, fully integrated into the track to enable a seamless end-to-end automated workflow.
